Nutriband Inc. (NASDAQ: NTRB) is a Healthcare company (Biotechnology) with a market capitalization of $68M. The Maz Rating grades it against the other companies in its sector.
Nutriband Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $5.59, Nutriband Inc. trades at 42.2x sales and 12.8x book value. Over the last twelve months it generated about $2M of revenue and a net loss of $7M. It runs a gross margin of 33.1%, an operating margin of -435.6% and a net margin of -430.4%. It shows return on equity of -109.0%, return on invested capital of -127.0% and a free cash flow yield of -5.3%. On the balance sheet: a debt-to-equity ratio of 0.04 and a current ratio of 4.21. Over the past 52 weeks the share price ranged from $2.80 to $9.19, with a beta of 1.93.
Nutriband Inc. does not currently pay a dividend.
1 Wall Street analyst rating covers the stock: 1 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain. Its development pipeline also includes other treatments, such as AVERSA buprenorphine and AVERSA methylphenidate. Additionally, Nutriband is working on exenatide for individuals with type 2 diabetes and follicle stimulating hormone as a treatment for infertility. The company also holds a licensing agreement with Rambam Med-Tech Ltd. to further the development of RAMBAM Closed System Transfer Devices. Nutriband Inc. was founded in 2016 and its main offices are located in Orlando, Florida.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of July 2026, Nutriband Inc. (NTRB) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.26% / 30% · (Cash+Inv) / Mkt Cap (36m) 4.61% / 30% · Interest income / Revenue 3.42% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.26% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 4.61% / 33% · Receivables / Mkt Cap (36m) 0.03% / 49% · Interest income / Revenue 3.42% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.26% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 4.61% / 33.33% · Receivables / Mkt Cap (24m) 0.03% / 33.33% · Interest income / Revenue 3.42% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 2.63% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 59.4% / 33.33% · Receivables / Avg Assets (4Q) 1.00% / 33.33% · Interest income / Revenue 3.42% / 5% | Fail |
| FTSE | Debt / Total Assets 3.09% / 33.33% · (Cash+ST Inv) / Total Assets 54.4% / 33.33% · (Cash+Recv) / Total Assets 54.7% / 33.33% · Interest income / Revenue 3.42% / 5% | Fail |
It depends on the standard you follow. As of July 2026, Nutriband Inc. (NTRB) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Nutriband Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 3.42% of each dividend: Nutriband Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated July 31, 2026 (Q2 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.